120 related articles for article (PubMed ID: 28029654)
21. [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Keshari RP; Zhang LY
Ai Zheng; 2009 Apr; 28(4):337-43. PubMed ID: 19622290
[TBL] [Abstract][Full Text] [Related]
22. Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism.
Nie S; Huang Y; Shi M; Qian X; Li H; Peng C; Kong B; Zou X; Shen S
Oncol Rep; 2018 Oct; 40(4):2137-2146. PubMed ID: 30066914
[TBL] [Abstract][Full Text] [Related]
23. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.
Yu B; Gu D; Zhang X; Liu B; Xie J
J Genet Genomics; 2017 Aug; 44(8):375-383. PubMed ID: 28847472
[TBL] [Abstract][Full Text] [Related]
24. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.
Hamada S; Satoh K; Hirota M; Kanno A; Umino J; Ito H; Masamune A; Kikuta K; Kume K; Shimosegawa T
J Cell Physiol; 2012 Feb; 227(2):729-38. PubMed ID: 21465479
[TBL] [Abstract][Full Text] [Related]
25. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
26. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
27. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes.
Jia Y; Chen J; Zhu H; Jia ZH; Cui MH
Oncol Rep; 2015 Nov; 34(5):2296-304. PubMed ID: 26324021
[TBL] [Abstract][Full Text] [Related]
28. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy.
Ding XW; Wu JH; Jiang CP
Life Sci; 2010 Apr; 86(17-18):631-7. PubMed ID: 20159023
[TBL] [Abstract][Full Text] [Related]
29. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
[TBL] [Abstract][Full Text] [Related]
30. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1
Chen B; Zhang D; Kuai J; Cheng M; Fang X; Li G
Tumour Biol; 2017 Jun; 39(6):1010428317715155. PubMed ID: 28639895
[TBL] [Abstract][Full Text] [Related]
33. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
[TBL] [Abstract][Full Text] [Related]
34. ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.
Wang H; Luo F; Zhu Z; Xu Z; Huang X; Ma R; He H; Zhu Y; Shao K; Zhao J
BMC Cancer; 2017 Mar; 17(1):222. PubMed ID: 28347288
[TBL] [Abstract][Full Text] [Related]
35. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
[TBL] [Abstract][Full Text] [Related]
37. Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.
Cederbye CN; Palshof JA; Hansen TP; Duun-Henriksen AK; Linnemann D; Stenvang J; Nielsen DL; Brünner N; Viuff BM
Sci Rep; 2016 Jun; 6():26997. PubMed ID: 27257141
[TBL] [Abstract][Full Text] [Related]
38. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
Yakisich JS; Venkatadri R; Azad N; Iyer AKV
J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
[TBL] [Abstract][Full Text] [Related]
39. LAT-1 functions as a promotor in gastric cancer associated with clinicopathologic features.
Wang J; Chen X; Su L; Li P; Liu B; Zhu Z
Biomed Pharmacother; 2013 Oct; 67(8):693-9. PubMed ID: 23809372
[TBL] [Abstract][Full Text] [Related]
40. SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway.
Wang J; Zhu XX; Liu L; Xue Y; Yang X; Zou HJ
Endocrine; 2016 Aug; 53(2):443-52. PubMed ID: 27022940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
